Viracta Therapeutics Inc (VIRX)
0.4942
-0.02
(-3.10%)
USD |
NASDAQ |
Jul 02, 16:00
0.4942
0.00 (0.00%)
After-Hours: 20:00
Viracta Therapeutics Research and Development Expense (Annual): 33.37M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 33.37M |
| December 31, 2022 | 26.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 23.86M |
| December 31, 2020 | 13.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
13.47M
Minimum
2020
33.37M
Maximum
2023
24.24M
Average
25.06M
Median
Research and Development Expense (Annual) Benchmarks
| XOMA Corp | 0.143M |
| Marinus Pharmaceuticals Inc | 99.39M |
| Cartesian Therapeutics Inc | 71.84M |
| Adial Pharmaceuticals Inc | 1.267M |
| NovaBay Pharmaceuticals Inc | 0.068M |